Skyrizi (risankizumab) is a new biologic for treating psoriasis. The first dose in Canada was injected at Charlton Health. This treatment is given by injection as 2 prefilled syringes starting at week 0, week 4 and then every 12 weeks. It works by blocking IL-23, a cytokine that promotes production of IL-17 in skin cells. The results in achieving complete skin clearance are impressive. This is the second medication in this family of biologics.
We are always proud to be on the front lines with new treatments. Make sure to stay tuned to our #WiseWordsWednesday blog to always be kept in the loop about these new innovations.
Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.
This week, many will return to school, and it's no secret that the back-to-school season…
Staying well hydrated is important in every season, but it becomes especially crucial during thesummer.…
Last week, on July 28th, we observed World Hepatitis Day, a day dedicated to raising…
Summer is a great time to get out and see new sights. Whether you're planning…
Now that the warmer weather is here, many of us are spending more time enjoying…
Biosimilars are becoming more common in Canada, offering patients trusted alternatives to the originator biologic medication. Biosimilars…